2型糖尿病治疗对精准糖尿病学的适用性如何?基于174项随机试验血糖控制数据的Meta回归分析
本研究采用Meta回归方法,纳入174项安慰剂对照随机试验(178个安慰剂组和272个活性治疗组,共86,940名参与者),评估治疗后HbA1c变异性及其预测因素。结果显示,活性治疗组与安慰剂组log(SD)的校正差值为0.037(95% CI:0.004,0.069),即活性治疗组HbA1c变异性小幅增加;药物类别中GLP-1受体激动剂导致的log(SD)差值最大。作者认为,精准医学方法在改善2型糖尿病血糖控制方面的潜力最多为中等。
要点
- 活性治疗组与安慰剂组log(SD)的校正差值为0.037(95% CI:0.004,0.069),提示活性治疗组HbA1c变异性小幅增加。
- 药物类别是解释该变异性增加的潜在预测因素,GLP-1受体激动剂导致的log(SD)差值最大。
- 作者认为精准医学方法在2型糖尿病血糖控制改善方面的潜力最多为中等。
核心结论
- 精准医学方法在2型糖尿病治疗中的潜力最多为中等,至少就血糖控制改善而言如此。
- GLP-1受体激动剂在血糖控制不佳个体中导致治疗后更大变异性的发现,应通过其他临床结局和不同研究设计进行重复和/或验证。
研究设计与样本
- Meta回归分析,纳入174项安慰剂对照随机试验,包括178个安慰剂组和272个活性治疗组,共86,940名参与者,评估治疗后HbA1c变异性及其潜在预测因素。
主要发现
- 活性治疗组与安慰剂组log(SD)的校正差值为0.037(95% CI:0.004,0.069),即活性治疗组HbA1c变异性小幅增加。
- 观察到药物类别是解释该变异性增加的潜在相关预测因素,GLP-1受体激动剂导致的log(SD)差值最大。
局限性
- GLP-1受体激动剂在血糖控制不佳个体中导致更大变异性的发现应通过其他临床结局和不同研究设计进行重复和/或验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: There are two prerequisites for the precision medicine approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in the case of treatment heterogeneity, we need to detect clinical predictors to identify people who would benefit from one treatment more than from others. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. Our aim was to apply this approach to the treatment of type 2 diabetes. METHODS: We performed a meta-regression analysis using information from 174 placebo-controlled randomised trials with 178 placebo and 272 verum (i.e. active treatment) arms including 86,940 participants with respect to the variability of glycaemic control as assessed by HbA1c after treatment and its potential predictors. RESULTS: The adjusted difference in log(SD) values between the verum and placebo arms was 0.037 (95% CI: 0.004, 0.069). That is, we found a small increase in the variability of HbA1c values after treatment in the verum arms. In addition, one potentially relevant predictor for explaining this increase, drug class, was observed, and GLP-1 receptor agonists yielded the largest differences in log(SD) values. CONCLUSIONS/INTERPRETATION: The potential of the precision medicine approach in the treatment of type 2 diabetes is modest at best, at least with regard to an improvement in glycaemic control. Our finding of a larger variability after treatment with GLP-1 receptor agonists in individuals with poor glycaemic control should be replicated and/or validated with other clinical outcomes and with different study designs. FUNDING: The research reported here received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. DATA AVAILABILITY: Two datasets (one for the log[SD] and one for the baseline-corrected log[SD]) to reproduce the analyses from this paper are available on https://zenodo.org/record/7956635 .
引用
- Kuss O, Opitz ME, Brandstetter LV, et al. How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials. Diabetologia. 2023. PMID: 37338539. doi:10.1007/s00125-023-05951-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。